Structural insights into Arylidenehydrazinyl Benzenesulfonamides as potent mycobacterial carbonic anhydrase inhibitors.

Authors

Pardeep Kumar, Anuradha Singampalli, Rani Bandela, Sri Mounika Bellapukonda, Sarvan Maddipatla, Aman Dalal, Ankita Devi, Srinivas Nanduri, Nitin Pal Kalia, Niccolo Paoletti, Claudiu T Supuran, Yaddanapudi Venkata Madhavi

Published in

Future medicinal chemistry. Volume 17. Issue 17. Pages 2131-2144. Epub Sep 02, 2025.

Abstract

To design, synthesize, and assess novel sulfonamide hydrazone derivatives as selective inhibitors of Mycobacterium tuberculosis carbonic anhydrase.
Two series of 4-(arylidenehydrazinyl)benzenesulfonamides (5a-r) and N-arylidene-4-methylbenzenesulfonohydrazides (6a-h) were synthesized and evaluated against recombinant MtCA isoforms 1 and 3, and human carbonic anhydrase isoforms I and II by enzyme inhibition assays. Molecular docking and molecular dynamics simulations assessed the binding stability and coordination with the active-site zinc ion. Anti-mycobacterial activity was determined by minimum inhibitory concentrations (MICs) against M. tuberculosis. Time-kill kinetics and cytotoxicity assays evaluated the bactericidal potential and selectivity of the compound toward mammalian cells.
The compounds showed potent inhibition of MtCA 3 and hCA II, with moderate activity against MtCA 1 and hCA I. Notably, compounds 3e and 3f exhibited K_i values of 0.0931 µM and 0.0984 µM, respectively, surpassing acetazolamide (K_i = 0.104 µM). Docking and simulations confirmed stable zinc coordination. MIC values ranged from 4 to 128 µg/mL. Time-kill and cytotoxicity studies confirmed rapid bactericidal activity and low mammalian toxicity.
These sulfonamide hydrazone derivatives demonstrate potent, selective MtCA inhibition, robust antimycobacterial efficacy, and favorable safety profiles, representing promising scaffolds for novel tuberculosis therapies with a novel mode of action.

PMID:
40891745
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.